Ocular Therapeutix, Inc. (OCUL:NASDAQ) closed at $6.50 on October 23, 2026, down 1.66% on the day. The stock trades 60.5% below its 52-week high of $16.44 and 8.3% above its 52-week low of $6.00. Over the past year, it lost 43.4%. Ocular Therapeutix, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, OCUL closed higher on 111 days (44%). Its best day was December 8, 2025 (+28.06%) and its worst was February 17, 2026 (-21.28%). The stock moved 10% or more in a single session 8 times. It opened at least 5% above the previous day's high 3 times.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the United States. It markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. The company's lead product includes DEXTENZA, which is in Phase III clinical trial for the treatment of post-surgical pain and inflammation, allergic conjunctivitis; and in Phase II clinical trial for the treatment of inflammatory dry eye disease. It is also developing OTX-TP, which is in Phase III clinical trial for glaucoma and ocular hypertension. In addition, the company has preclinical development of intravitreal depot with protein-based or small molecule drugs, including tyrosine kinase inhibitors, for the treatment of wet age-related macular degeneration and other retinal diseases. It has a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals, Inc. for the development of sustained release formulation of the vascular endothelial growth factor trap aflibercept for the treatment of wet age-related ma...
Find more stocks like OCUL with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.